Supplier News Breaks Archives
Natroba head lice solution ships to pharmacies
August 15th, 2011
THE WOODLANDS, Texas, and CARMEL, Ind. – Pernix Therapeutics Holdings Inc. and ParaPRO LLC have launched of Natroba Topical Suspension 0.9%, a pediatric treatment for head lice.
Approved by the Food and Drug Administration as a prescription treatment for children ages 4 years and older, Natroba treats head lice using spinosad, a compound derived from a soil microbe. Pernix co-promotes Natroba with ParaPRO, which developed the medication.
"Ever since Natroba received FDA approval earlier this year, there has been significant interest from parents and health care professionals all across the country who have requested information about product availability," stated Bill Culpepper, president of ParaPRO. "We believe that based on the high level of interest, there will be strong demand for this new and effective head lice treatment.
"We are delighted to announce that Natroba is now being shipped to pharmacies around the country, just in time for the back-to-school head lice season," Culpepper added. "In clinical trials, Natroba was shown to be nearly twice as effective as the most commonly prescribed head lice medication, permethrin 1%, and in those trials Natroba was proven effective without the need for extensive and time-consuming nit combing sessions.”
Each year in the United States there are an estimated 6 million to 12 million cases of head lice infestations, with most cases occurring in children ages 3 to 12, according to data from the Centers for Disease Control and Prevention cited by Pernix and ParaPRO.
"The launch of Natroba is another significant milestone for our company as we continue to diversify our product portfolio," commented Cooper Collins, president and chief executive officer of Pernix. "Natroba is an important new, easy-to-use and effective treatment option for parents of children suffering from a head lice infestation. We are pleased that the product is available for the upcoming school year."